Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Second-Quarter 2015 Financial Results

Recent Highlights Advanced FX006, company's lead program, for the treatment of moderate to severe osteoarthritis (OA) pain by completing patient enrollment in Phase 3 clinical trial ahead...
August 04, 2015 16:02 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Secures $30 Million in Debt Financing

Non-dilutive debt financing provides funding for manufacturing expansion for company's Phase 3 lead clinical candidate, FX006, for moderate to severe osteoarthritis (OA) pain BURLINGTON,...
August 04, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Expands Supply Capacity for FX006 by Entering Into Agreement With Patheon

- Adding Patheon as a contract manufacturer, in addition to Evonik Corporation, bolsters manufacturing capacity for planned commercialization of company's lead program BURLINGTON, Mass., Aug. 4,...
July 30, 2015 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Second-Quarter 2015 Financial Results on August 6, 2015

BURLINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its second-quarter 2015...
July 29, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Completes Enrollment in Phase 3 Clinical Trial With Lead Compound FX006 in Patients With Osteoarthritis of the Knee

With rapid enrollment in Phase 3 trial, the company expects to report topline data in first quarter of 2016, ahead of schedule Topline data from ongoing pivotal Phase 2b clinical trial also...
June 03, 2015 16:46 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics' Final FX006 Data From Completed Phase 2b Dose-Ranging Trial Published in Journal of Bone and Joint Surgery

BURLINGTON, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that a manuscript describing final study results from a completed Phase 2b clinical trial...
May 07, 2015 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports First-Quarter 2015 Financial Results

Key Highlights Announced a U.S. Department of Defense (DoD) grant worth approximately $2 million to conduct a Phase 2 clinical trial to study lead compound FX006 in active military and...
April 30, 2015 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report First-Quarter 2015 Financial Results on May 7, 2015

BURLINGTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2015...
April 29, 2015 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Awarded Approximately $2 Million From U.S. Department of Defense to Conduct Clinical Trial of FX006 in Military Personnel With Osteoarthritis of the Knee

BURLINGTON, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Department of Defense ("DoD") awarded the company a grant1 worth...
April 08, 2015 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at 14th Annual Needham Healthcare Conference

BURLINGTON, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the...